texas oncology more breakthroughs. more victories
Some of our cancer centers are experiencing issues.  View More Important Notifications x

Austin Midtown Research & Clinical Trials

Texas Oncology-Austin Midtown participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Texas Oncology-Austin Midtown (Expand)

Anal Cancer

STAR Ph3 Carbo/Pac NCMGA00012 MSCC

A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303) Read Moreabout STAR Ph3 Carbo/Pac NCMGA00012 MSCC

Phase: III

Bladder Cancer

Ph1 SGN-TGT Advanced Malignancies

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001) Read Moreabout Ph1 SGN-TGT Advanced Malignancies

Phase: I

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read Moreabout Ph1/2 AMG510 KRAS mut G12C Solid Tumors

Phase: II

NeoAdj Chemo +/- Nivo MIBC

A Phase 3 Randomized Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205 Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078) Read Moreabout NeoAdj Chemo +/- Nivo MIBC

Phase: III

PH3 Atez Bladder Can CTDNA+ (IMvigor)

A PHASE III DOUBLE-BLIND MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) VERSUS PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE INVASIVE BLADDER CANCER WHO ARE CTDNA POSITIVE FOLLOWING CYSTECTOMY (BO42843) Read Moreabout PH3 Atez Bladder Can CTDNA+ (IMvigor)

Phase: III

STAR PH 2 Enfortumab in Urothelial Pts-Cohort L

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002) Read Moreabout STAR PH 2 Enfortumab in Urothelial Pts-Cohort L

Phase: I/II

Blood Cancer

Ph2 Sub Mosunetuzumab B-cell malig

AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389) Read Moreabout Ph2 Sub Mosunetuzumab B-cell malig

Phase: II

Brain Cancer

A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy (STELLAR study)

Phase: III

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1

An International, Seamless Phase II/III Responsive Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)

Phase: II/III

EF-32 (TRIDENT): A PIVOTAL RANDOMIZED, OPEN-LABELSTUDY OF OPTUNE® (TTFIELDS, 200KHZ) CONCOMITANT WITHRADIATION THERAPY AND TEMOZOLOMIDE FOR THETREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA

Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)

Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE).

Breast Cancer

Ph3 GDC-9545+ Palbo +/- Letro HER2- BC

(BO41843)A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER Read Moreabout Ph3 GDC-9545+ Palbo +/- Letro HER2- BC

Phase: III

A Phase 0, Investigator Initiated Study, Evaluating the Impact of Omega 3 Free Fatty Acid Supplementation on Aromatase in Obese Postmenopausal Women with Estrogen Receptor Positive Breast Cancer

Phase: N/A

Ph1 SGN-TGT Advanced Malignancies

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001) Read Moreabout Ph1 SGN-TGT Advanced Malignancies

Phase: I

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

STAR Ph2 Trila Sacit Gove TNBC

A Phase 2 Single-Arm Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments at Least One in the Metastatic Setting (G1T28-213) Read Moreabout STAR Ph2 Trila Sacit Gove TNBC

Phase: II

Ph3 Gem Carbo BC Preserve 2

A Phase 3 Randomized Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2) (G1T28-208) Read Moreabout Ph3 Gem Carbo BC Preserve 2

Phase: III

PH3 Tras Deru HER2- BC

A Phase 3 Randomized Multi-center Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) (D9670C00001) Read Moreabout PH3 Tras Deru HER2- BC

Phase: III

Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA

A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554) Read Moreabout Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA

Phase: III

Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)

A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001) Read Moreabout Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)

Phase: III

Ph3 HER2+/ER+ BC

A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571) Read Moreabout Ph3 HER2+/ER+ BC

Phase: III

Ph3 Sac Gov Pemb vs PC BC

A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (GS-US-592-6173) Read Moreabout Ph3 Sac Gov Pemb vs PC BC

Phase: III

Ph3 Sac GOv vs PC BC

A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238) Read Moreabout Ph3 Sac GOv vs PC BC

Phase: III

Ph3 LY3484356 ER+ HER2- BC

EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC) Read Moreabout Ph3 LY3484356 ER+ HER2- BC

Phase: III

Ph 3 BYL719 + nabpax TNBC PIK3CA

EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301) Read Moreabout Ph 3 BYL719 + nabpax TNBC PIK3CA

Phase: III

PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA

EPIK-B4: A Phase II multicenter randomized open-label active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+ HER2- advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202) Read Moreabout PH2 Dapa Met Fulv HR+ HER2- BC PIK3CA

Phase: II

Ph3 Nira Her2- triple- BC ctDNA (ZEST)

GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY Read Moreabout Ph3 Nira Her2- triple- BC ctDNA (ZEST)

Phase: III

FLEX Registry: Evaluate New Gene Express

MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Read Moreabout FLEX Registry: Evaluate New Gene Express

Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4)

SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001) Read Moreabout Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4)

Phase: III

Carcinoid

STAR Ph3 Carbo/Pac NCMGA00012 MSCC

A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303) Read Moreabout STAR Ph3 Carbo/Pac NCMGA00012 MSCC

Phase: III

Colon Cancer

Ph1b AMG 510 MVASI Combo KRAS CRC

20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with MVASI® and FOLFIRI and in Combination with MVASI® and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol M) Read Moreabout Ph1b AMG 510 MVASI Combo KRAS CRC

Phase: I

Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C

20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C) Read Moreabout Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C

Phase: I

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read Moreabout Ph1/2 AMG510 KRAS mut G12C Solid Tumors

Phase: II

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

STAR Ph3 MRTX849 Cetux KRAS G12C CC

A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010) Read Moreabout STAR Ph3 MRTX849 Cetux KRAS G12C CC

Phase: III

BESPOKE ctDNA Colorectal Cancer

BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer (20-041-NCP) Read Moreabout BESPOKE ctDNA Colorectal Cancer

Endometrial Cancer

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read Moreabout Ph1/2 AMG510 KRAS mut G12C Solid Tumors

Phase: II

Esophageal Cancer

Ph1b/3 Bema + Nivo Gastric GEJ FGFR2b

(20210098) A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102) Read Moreabout Ph1b/3 Bema + Nivo Gastric GEJ FGFR2b

Phase: I

Gastric Cancer

Ph1b/3 Bema + Nivo Gastric GEJ FGFR2b

(20210098) A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102) Read Moreabout Ph1b/3 Bema + Nivo Gastric GEJ FGFR2b

Phase: I

Ph1 SGN-TGT Advanced Malignancies

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001) Read Moreabout Ph1 SGN-TGT Advanced Malignancies

Phase: I

Head and Neck Cancer

STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC

A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01) Read Moreabout STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC

Phase: I

Ph1 SGN-TGT Advanced Malignancies

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001) Read Moreabout Ph1 SGN-TGT Advanced Malignancies

Phase: I

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

Ph1b AhRi BAY 2416964 + Pembro ST

An open-label Phase 1b dose escalation and expansion study to evaluate the safety tolerability maximum tolerated or administered dose pharmacokinetics pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in combination with pembrolizumab in participants with advanced solid tumors (BAY 2416964 / 21343) Read Moreabout Ph1b AhRi BAY 2416964 + Pembro ST

Phase: I

Hematologic

PH2 Brentux+CHP In Tx Naive PTCL

A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032) Read Moreabout PH2 Brentux+CHP In Tx Naive PTCL

Phase: II

Leukemia

PH2 Brentux+CHP In Tx Naive PTCL

A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032) Read Moreabout PH2 Brentux+CHP In Tx Naive PTCL

Phase: II

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II

Ph3 Ascim vs PC TKI new dx Ph+ CML

A phase III multi-center open-label randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12301) Read Moreabout Ph3 Ascim vs PC TKI new dx Ph+ CML

Phase: III

PH3 Ven+G vs FCR/BR in Fit untreated CLL

A PROSPECTIVE OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION (CO41685) Read Moreabout PH3 Ven+G vs FCR/BR in Fit untreated CLL

Phase: III

STAR Ph3b ABL001 in CML-CP +/-T315i

An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04) Read Moreabout STAR Ph3b ABL001 in CML-CP +/-T315i

Phase: III/IV

Lung Cancer

Ph1b AMG 510 in Combo NSCLC KRAS p.G12C

20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Carboplatin and Pemetrexed; with Docetaxel; or with Carboplatin and Paclitaxel in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol F) Read Moreabout Ph1b AMG 510 in Combo NSCLC KRAS p.G12C

Phase: I

Ph1b AMG510 + Pembro NSCLC KRAS G12C

20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Pembrolizumab in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol I) Read Moreabout Ph1b AMG510 + Pembro NSCLC KRAS G12C

Phase: I

Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C

20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C) Read Moreabout Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C

Phase: I

Ph1b Sotora NSCLC KRAS p.G12C Brain Met

20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation with Brain Metastases (CodeBreak 101 Subprotocol G) Read Moreabout Ph1b Sotora NSCLC KRAS p.G12C Brain Met

Phase: I

Ph1 SGN-TGT Advanced Malignancies

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001) Read Moreabout Ph1 SGN-TGT Advanced Malignancies

Phase: I

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read Moreabout Ph1/2 AMG510 KRAS mut G12C Solid Tumors

Phase: II

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203) Read Moreabout STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

Phase: I/II

Ph2 Bren Vedo + Pembro ST prior PD-1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033) Read Moreabout Ph2 Bren Vedo + Pembro ST prior PD-1

Phase: II

STAR Ph2 MRTX849 Pembro NSCLC KRAS

A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007) Read Moreabout STAR Ph2 MRTX849 Pembro NSCLC KRAS

Phase: II

STAR Ph3 Ami Laz EGFR-mut NSCLC

A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002) Read Moreabout STAR Ph3 Ami Laz EGFR-mut NSCLC

Phase: III

A phase 3, open-label, 3-cohort randomized study of N-803 in combination with current standard of care vs standard of care as first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC).

Phase: II

STAR PH3 EGFRm stage2/3b NSCLC

A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001) Read Moreabout STAR PH3 EGFRm stage2/3b NSCLC

Phase: III

STAR: PH1/3 Biomarker unresectable stg3 NSCLC

A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777) Read Moreabout STAR: PH1/3 Biomarker unresectable stg3 NSCLC

Phase: III

STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX) Read Moreabout STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

Phase: III

Ph2 Tomivosertib+Anti-PD-L1 NSCLC

A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011) Read Moreabout Ph2 Tomivosertib+Anti-PD-L1 NSCLC

Phase: II

STAR PH3 JNJ-61186372 Peme EGFR NSCLC

A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001) Read Moreabout STAR PH3 JNJ-61186372 Peme EGFR NSCLC

Phase: III

Ph1b AhRi BAY 2416964 + Pembro ST

An open-label Phase 1b dose escalation and expansion study to evaluate the safety tolerability maximum tolerated or administered dose pharmacokinetics pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in combination with pembrolizumab in participants with advanced solid tumors (BAY 2416964 / 21343) Read Moreabout Ph1b AhRi BAY 2416964 + Pembro ST

Phase: I

Ph 1 PF-06821497 R/R SCLC CRPC & FL

C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL) Read Moreabout Ph 1 PF-06821497 R/R SCLC CRPC & FL

Phase: I

Ph 3 Nivo+CCRT vs CCRT Durva la NSCLC

CA20973L: A Phase 3 Randomized Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC) Read Moreabout Ph 3 Nivo+CCRT vs CCRT Durva la NSCLC

Phase: III

Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4)

D9103C00001: A Phase III Randomized Placebo-controlled Double-blind Multi-center International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Read Moreabout Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4)

Phase: III

Biomarker status NSCLC

MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361) Read Moreabout Biomarker status NSCLC

Ph2 Nap r/r NSCLC

NT-NAP-102-1: PHASE 2a OPEN-LABEL MULTICENTER TRIAL OF NAPTUMOMAB ESTAFENATOX (NAP) IN COMBINATION WITH DOCETAXEL FOLLOWING OBINUTUZUMAB PRETREATMENT IN SUBJECTS WITH CHECKPOINT INHIBITOR PRETREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER Read Moreabout Ph2 Nap r/r NSCLC

Phase: II

Ph3 SAR408701 vs Doce NSCLC CEACAM5+

Randomized Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic non-squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors (EFC15858) Read Moreabout Ph3 SAR408701 vs Doce NSCLC CEACAM5+

Phase: III

STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C

RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies Read Moreabout STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C

Phase: II

Lymphomas

STAR BV in pts w/1L cHL or PTCL

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy Read Moreabout STAR BV in pts w/1L cHL or PTCL

Phase: II

PH2 Brentux+CHP In Tx Naive PTCL

A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032) Read Moreabout PH2 Brentux+CHP In Tx Naive PTCL

Phase: II

Ph1 SGN-TGT Advanced Malignancies

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001) Read Moreabout Ph1 SGN-TGT Advanced Malignancies

Phase: I

Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph

A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302) Read Moreabout Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph

Phase: I

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II

Ph2 Lonca-R DLBCL

A Phase 2 open-label study of loncastuximab tesirine in combination with rituximab (Lonca-R) in previously untreated unfit/frail patients with diffuse large B-cell lymphoma (DLBCL) (LOTIS-9/ ADCT-402-203) Read Moreabout Ph2 Lonca-R DLBCL

Phase: II

Ph3 LOXO-305 vs PC of BTK in MCL

A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019) Read Moreabout Ph3 LOXO-305 vs PC of BTK in MCL

Phase: III

Ph3 LOXO-305 vs. InvChoice in CLL/SLL

A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020) Read Moreabout Ph3 LOXO-305 vs. InvChoice in CLL/SLL

Phase: III

Ph2 Sub Mosunetuzumab B-cell malig

AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389) Read Moreabout Ph2 Sub Mosunetuzumab B-cell malig

Phase: II

Ph 1 PF-06821497 R/R SCLC CRPC & FL

C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL) Read Moreabout Ph 1 PF-06821497 R/R SCLC CRPC & FL

Phase: I

Ph3 Tafa+ Lena R-CHOP B-Cell Lymp

MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Read Moreabout Ph3 Tafa+ Lena R-CHOP B-Cell Lymp

Phase: III

Melanoma

Ph1 SGN-TGT Advanced Malignancies

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001) Read Moreabout Ph1 SGN-TGT Advanced Malignancies

Phase: I

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

Ph2 Bren Vedo + Pembro ST prior PD-1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033) Read Moreabout Ph2 Bren Vedo + Pembro ST prior PD-1

Phase: II

A Phase 3, Randomized ,Double-blind Study of Adjuvant Immunotherapy with Relalimab+Nivolumab versus Nivolumab after Complete Resection of Stage III-IV Melanoma

Phase: III

Myelofibrosis

STAR Ph2 Selinexor vs PC MF

A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035) Read Moreabout STAR Ph2 Selinexor vs PC MF

Phase: II

STAR Ph3 Navi Ruxo Myelofibrosis

M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1) Read Moreabout STAR Ph3 Navi Ruxo Myelofibrosis

Phase: III

Myelomas

Ph1 SEA-BCMA R/R MM

A phase 1 study of SEA-BCMA in patients with relapsed or refractory multiple myeloma (SGNBCMA-001) Read Moreabout Ph1 SEA-BCMA R/R MM

Phase: I

Ph2 Dara Lena Dexa (DRd) MM I

A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285) Read Moreabout Ph2 Dara Lena Dexa (DRd) MM I

Phase: II

PH3 Dara/Len vs Len NDMM

A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021) Read Moreabout PH3 Dara/Len vs Len NDMM

Phase: III

Ovarian Cancer

Ph1 SGN-TGT Advanced Malignancies

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001) Read Moreabout Ph1 SGN-TGT Advanced Malignancies

Phase: I

STAR Ph2 VS-6766 Fak-Inhib LGSOC

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052) Read Moreabout STAR Ph2 VS-6766 Fak-Inhib LGSOC

Phase: II

Pancreatic Cancer

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read Moreabout Ph1/2 AMG510 KRAS mut G12C Solid Tumors

Phase: II

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC

A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301) Read Moreabout Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC

Phase: III

GRECO-2: A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer.

Prostate Cancer

STAR PH3 Nirap Abira HRR mCSPC

A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002) Read Moreabout STAR PH3 Nirap Abira HRR mCSPC

Phase: III

STAR PH3 Abi+/-Capi mHSPC CAPItello-281

A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001 Read Moreabout STAR PH3 Abi+/-Capi mHSPC CAPItello-281

Phase: III

PH3 Place Capi+ Doce Place+ Doce mCRPC

A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001) Read Moreabout PH3 Place Capi+ Doce Place+ Doce mCRPC

Phase: III

Biomarker DNA Defect Men Prostate

Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002) Read Moreabout Biomarker DNA Defect Men Prostate

Ph 1 PF-06821497 R/R SCLC CRPC & FL

C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL) Read Moreabout Ph 1 PF-06821497 R/R SCLC CRPC & FL

Phase: I

Rectal Cancer

BESPOKE ctDNA Colorectal Cancer

BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer (20-041-NCP) Read Moreabout BESPOKE ctDNA Colorectal Cancer

Renal Cancer

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

Skin Cancer

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

Solid Tumors

Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C

20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H) Read Moreabout Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C

Phase: I

Ph1b AMG 510 + Palboc ST KRAS p.G12C

20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J) Read Moreabout Ph1b AMG 510 + Palboc ST KRAS p.G12C

Phase: I

Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C

20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C) Read Moreabout Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C

Phase: I

Ph1/2 FIH BMS-986249 + Nivo Solid Tumor

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors Read Moreabout Ph1/2 FIH BMS-986249 + Nivo Solid Tumor

Phase: I

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read Moreabout STAR Ph1/2 MRTX849 Solids KRAS G12C

Phase: I/II

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2 Open-label Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read Moreabout Ph1/2 AMG510 KRAS mut G12C Solid Tumors

Phase: II

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

Ph2 Bren Vedo + Pembro ST prior PD-1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033) Read Moreabout Ph2 Bren Vedo + Pembro ST prior PD-1

Phase: II

A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations

Phase: II

Ph 1 PF-06821497 R/R SCLC CRPC & FL

C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL) Read Moreabout Ph 1 PF-06821497 R/R SCLC CRPC & FL

Phase: I

Ph2 Tumor-Agnostic Precision TAPISTRY

TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932) Read Moreabout Ph2 Tumor-Agnostic Precision TAPISTRY

Phase: II

Urothelial Cancer

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (CA027002) Read Moreabout Phase 1/2a BMS-986253 + Nivo

Phase: I/II

STAR PH 2 Enfortumab in Urothelial Pts-Cohort L

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002) Read Moreabout STAR PH 2 Enfortumab in Urothelial Pts-Cohort L

Phase: I/II

Ph1b AhRi BAY 2416964 + Pembro ST

An open-label Phase 1b dose escalation and expansion study to evaluate the safety tolerability maximum tolerated or administered dose pharmacokinetics pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in combination with pembrolizumab in participants with advanced solid tumors (BAY 2416964 / 21343) Read Moreabout Ph1b AhRi BAY 2416964 + Pembro ST

Phase: I